10:18 EDT BridgeBio (BBIO) jumps 12% to $83.18 as Pfizer (PFE) confirms tafamidis settlement
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio could trade to $90-$110 on Pfizer settlement, says Mizuho
- Apparent Hikma settlement ‘key positive’ for BridgeBio, says Barclays
- 3 Best Stocks to Buy This Week, According to Analysts – April 26-May 1
- BridgeBio Buy Rating Reiterated as Analyst Sees Extended Patent Runway, Delayed Tafamidis Competition and Maintains $100 Price Target
- Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls